Log in to your Inderes Free account to see all free content on this page.
Immunovia
1.64 SEK +0.49%Be the first to follow this company
Immunovia is a biotechnology company. The company's research and development is focused on molecular diagnostics, where the business focuses on driving the development and change of current working methods for diagnosing complex cancers and immune diseases. The vision is to establish blood-based tests to be able to identify different types of pancreatic cancer at an early stage. The company was founded in 2007 and is headquartered in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
IMMNOV
Daily low / high price
1.6 / 1.778
SEK
Market cap
74.27M SEK
Turnover
730.08K SEK
Volume
441K
Financial calendar
Interim report
22.08.2024
Interim report
14.11.2024
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Försäkringsbolaget Avanza Pension | 9.9 % | 9.9 % |
Carl Borrebaeck | 3.8 % | 3.8 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Immunovia AB: Immunovia's new lab staffed and operational after rapid implementation
Immunovia AB: BULLETIN FROM THE ANNUAL GENERAL MEETING ON 19 JUNE 2024 IN IMMUNOVIA AB (PUBL)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio